PanMETAI integrates ¹H NMR metabolomics with next-gen AI to provide a non-invasive, precision early screening solution for pancreatic cancer. Overcoming early detection barriers, it achieves a remarkable AUC of 0.95 for Stage I/II lesions. Backed by cross-national validation, standardized scalability, and a publication in Nature Communications, this pioneering platform holds immense commercial potential to revolutionize the global precision oncology market.

PanMETAI pioneers a multimodal ¹H NMR metabolomics-AI diagnostic platform, overcoming traditional single-biomarker limits. Powered by the next-gen TabPFN model and standardized quantitative protocols, it eliminates batch effects and provides SHAP-driven explainability. It achieves an AUC of 0.95 for detecting Stage I/II early lesions and maintains cross-national robustness in blind cohorts (AUC >0.90), demonstrating unprecedented clinical accuracy.

PanMETAI offers a non-invasive screening solution for early pancreatic cancer, addressing the limitations of CA19-9. Targeting high-risk groups, its "plug-and-play" ¹H NMR platform ensures global scalability for centralized lab services and CDSS. Validated by multinational cohorts (AUC >0.9) and published in Nature Communications, PanMETAI holds massive commercial potential with TW/US patents, ready to revolutionize global precision oncology screening and early intervention.